

## CONSTELLIUM SE 2026 ANNUAL GENERAL MEETING VOTING RESULTS

Constellium SE (the “Company”) held its Annual General Meeting of Shareholders on May 21, 2026. The proposals for the appointment of Ingrid Joerg and the re-appointment of John Ormerod to the Company’s Board of Directors for a period of three years following the Annual General Meeting, passed.

The Company’s shareholders approved, on an advisory basis, “one year” as the frequency for holding an advisory (non-binding) vote on the compensation of the Company’s named executive officers. In light of such vote, the Company has determined to hold the advisory (non-binding) vote on the compensation of the Company’s named executive officers every year. The results for the remainder of the proposals are as set forth below.

\* For the purposes of French law, broker non-votes are treated as abstentions. Therefore, in terms of the voting results, broker non-votes, like other abstentions, were not counted as a vote cast on the applicable proposal.

The voting results are as follows:

1. Ratification of the interim appointment of Ms. Ingrid Joerg as a director

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
97,942,587	320,964	80,305	10,462,884

2. Appointment of Ms. Ingrid Joerg as a director for a term of three years

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
97,919,555	343,694	80,607	10,462,884

3. Re-appointment of Mr. John Ormerod as a director for a term of three years

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
82,318,163	15,907,876	117,817	10,462,884

4. Approval, on an advisory (non-binding) basis, of the 2025 compensation of the Company’s named executive officers

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
79,852,601	5,788,962	12,702,293	10,462,884

5. Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company’s named executive officers every year

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
98,273,291	31,220	39,345	10,462,884

6. Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's named executive officers every two years

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
2,204,018	95,895,777	244,061	10,462,884

7. Advisory (non-binding) vote to hold an advisory (non-binding) vote on the compensation of the Company's named executive officers every three years

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
2,195,685	95,903,685	244,486	10,462,884

8. Approval of the statutory financial statements and transactions for the fiscal year ended December 31, 2025

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>
107,959,981	8,556	838,203

9. Approval of the consolidated financial statements and transactions for the fiscal year ended December 31, 2025

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>
107,958,765	8,373	839,602

10. Discharge (quitus) of the directors, the Chief Executive Officer, and the Statutory Auditors of the Company in respect of the performance of their duties for the fiscal year ended December 31, 2025

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
84,508,508	13,015,971	819,377	10,462,884

11. Allocation of the results of the Company for the fiscal year ended December 31, 2025

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>
108,658,184	9,365	139,191

12. Approval of the aggregate maximum amount of the directors' annual fixed fees

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
98,208,852	41,092	93,912	10,462,884

13. Authorization to be given to the Board of Directors for the repurchase by the Company of its own shares in accordance with article L. 225-209-2 of the French Commercial Code

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>
108,617,538	23,922	165,280

14. Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling shares acquired pursuant to the authorization for the Company to repurchase its own shares in accordance with the provisions of article L. 225-209-2 of the French Commercial Code

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>
108,728,505	20,320	57,915

15. Authorization to be given to the Board of Directors to reduce the Company's share capital by canceling the shares acquired by the Company pursuant to the provisions of article L. 225-208 of the French Commercial Code

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>
108,724,554	24,190	57,996

- 16 Powers to carry out formalities

<u>Voted For</u>	<u>Voted Against</u>	<u>Abstained</u>	<u>Broker Non-Votes*</u>
98,227,432	8,580	107,844	10,462,884